Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
15 pending office actions • 6 art units • 14 examiners • 0 of 15 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Sage Therapeutics LLC manages a robust patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company is currently navigating 15 pending office actions, indicating a high level of activity and ongoing negotiation with the USPTO. These actions are spread across 6 distinct art units, which suggests a broad and complex range of pharmaceutical innovations that span multiple specialized examination groups.
The prosecution effort involves 14 distinct examiners, reflecting a highly decentralized examination process. LEE, WILLIAM Y is the busiest examiner for this portfolio, currently overseeing 2 busiest examiner pending office actions. For a practitioner, the involvement of 14 distinct examiners means that prosecution strategies must be highly adaptable, as each examiner may have different interpretations of the 15 pending office actions and the underlying biotechnology claims.
With 6 distinct art units involved, the portfolio's success depends on navigating various technical standards and examiner preferences. The fact that LEE, WILLIAM Y holds 2 busiest examiner pending office actions shows that even the most active examiner only handles a small fraction of the total 15 pending office actions. This diversity in the Biotechnology & Pharmaceuticals space requires a comprehensive management approach to ensure consistency across the 14 distinct examiners.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (33%) |
| §112 only | 3 (20%) |
| Double-patenting only | 1 (7%) |
| Double-patenting + other | 4 (27%) |
| Multi-statute (no §101) | 2 (13%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, WILLIAM Y | 2 | 47.9% | +34.1% |
| FERGUSON, JALISA HOLMES | 1 | 61.1% | +43.8% |
| COLEMAN, BRENDA LIBBY | 1 | 74.9% | +15.5% |
| CHONG, YONG SOO | 1 | 43.8% | +41.6% |
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.4% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| ENGLISH, CONNOR KENNEDY | 1 | 60.0% | +51.3% |
| SUNSHINE, HANNAH LOUISE | 1 | 62.5% | +24.9% |
| ELENISTE, PIERRE PAUL | 1 | 35.5% | +31.2% |
| BORALSKY, LUKE ALAN | 1 | 66.7% | +44.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18694572 | DEUTERATED POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | INAM, SAHAR | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18719194 | COMBINATION OF MUSCARINIC RECEPTOR POSITIVE MODULATORS AND NMDA POSITIVE ALLOSTERIC MODULATORS | CHONG, YONG SOO | — |
| 18685603 | POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | ENGLISH, CONNOR KENNEDY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18550724 | A 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER | ELENISTE, PIERRE PAUL | 42d overdue |
| 18793028 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | FERGUSON, JALISA HOLMES | — |
| 18741425 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | COLEMAN, BRENDA LIBBY | — |
| 18719194 | COMBINATION OF MUSCARINIC RECEPTOR POSITIVE MODULATORS AND NMDA POSITIVE ALLOSTERIC MODULATORS | CHONG, YONG SOO | — |
| 18636563 | C7, C12, AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | COUGHLIN, MATTHEW P | — |
| 18685603 | POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | ENGLISH, CONNOR KENNEDY | — |
| 18581595 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | LEE, WILLIAM Y | — |
| 18568624 | NEUROACTIVE STEROID FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SUNSHINE, HANNAH LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1628 | 3 |
| 1622 | 2 |
| 1625 | 2 |
| 1623 | 2 |
| 1647 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18793028 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | FERGUSON, JALISA HOLMES | — | DP | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18741425 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | COLEMAN, BRENDA LIBBY | — | §112 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18719194 | COMBINATION OF MUSCARINIC RECEPTOR POSITIVE MODULATORS AND NMDA POSITIVE ALLOSTERIC MODULATORS | CHONG, YONG SOO | — | §102§103 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18636563 | C7, C12, AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | COUGHLIN, MATTHEW P | — | §112 | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18694572 | DEUTERATED POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | INAM, SAHAR | 1622 | §103 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18685603 | POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | ENGLISH, CONNOR KENNEDY | 1625 | §103§112 | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18581595 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | LEE, WILLIAM Y | 1623 | §112 | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18568624 | NEUROACTIVE STEROID FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SUNSHINE, HANNAH LOUISE | 1647 | §102§103DP | Final Rejection | — | Pending | Dec 08, 2023 |
| 18550724 | A 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER | ELENISTE, PIERRE PAUL | 1622 | §103Other | Non-Final OA | 42d overdue | Pending | Sep 15, 2023 |
| 18263189 | USE OF NEUROACTIVE STEROIDS FOR TREATMENT OF SEXUAL DYSFUNCTION | BORALSKY, LUKE ALAN | 1624 | §102§103DPOther | Non-Final OA | — | Pending | Jul 27, 2023 |
| 18201885 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | MOU, LIYUAN | 1628 | §103Other | Final Rejection | 10d overdue | Pending | May 25, 2023 |
| 17579541 | FORMULATIONS OF 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOF | CHANDRAKUMAR, NIZAL S | 1625 | §103Other | Final Rejection | 124d overdue | Pending | Jan 19, 2022 |
| 17416367 | 3.ALPHA.-HYDROXY-17.BETA.-AMIDE NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | CLARK, AMY LYNN | 1628 | §103 | Final Rejection | — | Pending | Jun 18, 2021 |
| 16955714 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | RODRIGUEZ, RAYNA B | 1628 | §103DP | Final Rejection | — | Pending | May 26, 2021 |
| 17251475 | A 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOF | LEE, WILLIAM Y | 1623 | §103DP | Final Rejection | — | Pending | Dec 11, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial